BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Quintessence Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer Meeting


4/14/2008 2:11:01 PM

MADISON, WISCONSIN— At the Annual Meeting of the American Association for Cancer Research today, Quintessence Biosciences presented the results of the IND-enabling toxicology studies for the Company’s lead cancer drug candidate, QBI-139. The toxicology results are a critical component of advancing a drug into human clinical trials.

QBI-139 is a potent anticancer agent based on the EVade™ Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new cancer drug target, with analogs of the human protein, pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown an exceptional safety profile and outstanding tumor growth inhibition in vivo against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. Quintessence projects a Phase 1 clinical trial to treat patients with solid tumors with QBI-139 will begin in the summer of 2008, subject to U.S. Food and Drug Administration (FDA) review.

“The toxicology results indicate that QBI-139 is tolerated at much higher dose levels than similar drugs under development,” said Quintessence Biosciences COO Dr. Laura Strong. “Since drugs with a similar mechanism of action have demonstrated clinical benefit, we are optimistic that QBI-139 treatment will provide a significant advance in cancer therapy and will demonstrate the utility of ribonuclease therapies in treating cancer patients.”

About Quintessence Biosciences, Inc. Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is anticipated to enter a Phase 1 clinical trial in summer 2008. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the American Association for Cancer Research Annual Meeting Each year, the American Association for Cancer Research (AACR) brings together scientists and other professionals from around the world to learn about new and significant discoveries in basic, clinical, and translational cancer research. This year more than 17,000 participants from 60 countries will gather to discuss an estimated 6,000 abstracts and to hear more than 500 invited presentations. Scientific award lectures, grant writing workshops, networking events, and educational sessions will round out the comprehensive program. For more information, visit www.aacr.org.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES